Calendrier des promotions Theratechnologies Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Paramètres de base
IPO date
2016-01-04
ISIN
CA88338H1001
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 0.6898 | 10 |
P/BV | -2.34 | 0 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -12.67 | 0 |
ROE | 36 | 9 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | 6.63 | 0 |
Debt/Ratio | 0.855 | 9 |
Debt/Equity | -3.11 | 10 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | 29.9 | 4 |
Rentabilité Ebitda, % | -174.77 | 0 |
Rentabilité EPS, % | -42.84 | 0 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 2.48 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 2.58 $ | 0 $ | 0 $ | -3.88 % | 0 % | 0 % |
common.calendar.number_days.30d | 2.64 $ | 2.48 $ | 2.6 $ | -6.06 % | 0 % | 0 % |
common.calendar.number_days.90d | 1.94 $ | 1.33 $ | 2.92 $ | 27.84 % | 0 % | 0 % |
common.calendar.number_days.180d | 1.71 $ | 1.33 $ | 2.92 $ | 45.45 % | 0 % | 0 % |
common.calendar.number_days.1y | 1.29 $ | 1.17 $ | 2.92 $ | 93 % | 0 % | 0 % |
common.calendar.number_days.3y | 8.6 $ | 0.89 $ | 9.68 $ | -71.16 % | 0 % | 0 % |
common.calendar.number_days.5y | 2.44 $ | 0.89 $ | 9.68 $ | 1.64 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.89 $ | 0.89 $ | 11.24 $ | 278.65 % | 0 % | 0 % |
common.calendar.number_days.ytd | 1.44 $ | 1.33 $ | 2.92 $ | 72.22 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Mr. Paul Lévesque | President, CEO & Director | 1.18M | 1964 (61 année) |
Mr. Philippe Dubuc M.B.A., MBA | Senior VP & CFO | 432.31k | 1967 (58 années) |
Mr. Jocelyn Lafond L.L.M., LL.B. | General Counsel & Corporate Secretary | 316.29k | 1968 (57 années) |
Dr. Christian Marsolais Ph.D. | Senior VP & Chief Medical Officer | 434.61k | 1963 (62 année) |
Mr. John Leasure | Global Commercial Officer | 420.91k | 1965 (60 années) |
Hon. Andre Dupras M.Sc. | Vice President of Human Resources | N/A | 1964 (61 année) |
Informations sur l'entreprise
Adresse: Canada, Montreal. QC HA T, 2015 Peel Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.theratech.com
Site web: https://www.theratech.com